Journal article icon

Journal article

Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease

Abstract:

Sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, lowers blood glucose when administered as monotherapy or in combination with other antihyperglycemic agents. TECOS will evaluate the effects of adding sitagliptin to usual diabetes care on cardiovascular outcomes and clinical safety. TECOS is a pragmatic, academically run, multinational, randomized, double-blind, placebo-controlled, event-driven trial recruiting approximately 14,000 patients in 38 countries who have type 2 diabetes (T2DM)...

Expand abstract

Actions


Access Document


Publisher copy:
10.1016/j.ahj.2013.09.003

Authors


Journal:
American Heart Journal More from this journal
Volume:
166
Issue:
6
Publication date:
2013-12-01
DOI:
EISSN:
1097-6744
ISSN:
0002-8703
Language:
English
Pubs id:
pubs:443315
UUID:
uuid:8c2953db-474b-44fa-9194-30d3249a7000
Local pid:
pubs:443315
Source identifiers:
443315
Deposit date:
2014-08-21

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP